The primary aim of this study is to determine types and prevalence of residual pulmonary damage after hospital admission for acute COVID‐19. In particular, we aim at determining the prevalence of clinically “silent” pulmonary perfusion abnormalities…
ID
Bron
Verkorte titel
Aandoening
COVID-19
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
-Prevalence of residual lung damage (per type) at 3 and 12 month
-Estimated percentage of lung parenchyma affected by various types of diffuse lung damage (e.g., ground glass, consolidation, perfusion abnormalities)
-Number of lung segments affected by focal lung damage (e.g., traction bronchiectasis, residual lung emboli)
-Predictors of pulmonary damage after acute COVID‐19
Achtergrond van het onderzoek
Included patients will undergo a CT angiography instead of routine chest imaging after 3 months to be able to assess all types of pulmonary damage, including perfusion abnormalities, and a low‐dose CT after 12 months to establish chronicity of pulmonary damage.
Doel van het onderzoek
The primary aim of this study is to determine types and prevalence of residual pulmonary damage after hospital admission for acute COVID‐19. In particular, we aim at determining the prevalence of clinically “silent” pulmonary perfusion abnormalities and establish the connection between current complaints and lung damage as well as the relation between clinical factors during hospitalization and residual lung damage. The ultimate goal is to find predictors, modifiable by treatment during or after the hospital stay, that affect long‐term outcome positively. With this study we aim at better understanding of the chronic phase of the disease and of how adverse outcomes might be prevented.
Onderzoeksopzet
3 months and 12 months after acute COVID-19
Onderzoeksproduct en/of interventie
CT angiography at 3 months and chest CT low dose at 12 months after acute COVID-19 infection
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
● Hospital admission for COVID‐19
● CT during admission with CO‐RADS >=3
● Informed consent
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
● Age < 18
● Pregnancy
● Renal failure (MDRD < 30 ml/kg/1,73m^2)
● Allergic reaction to iodine containing intravenous contrast media
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL8765 |
| Ander register | CMO Regio Arnhem-Nijmegen : 2020-6637 |